TRINITY BIOTECH PLC (NASDAQ: TRIB) filed a 424B3 prospectus supplement registering up to 705,659,320 ordinary shares — equivalent to approximately 35,282,966 American Depositary Shares — for resale by YA II PN, Ltd., an entity affiliated with Yorkville Advisors. The registered shares represent roughly 187% of the company's approximately 377 million ordinary shares currently outstanding.
The shares are issuable under a Standby Equity Purchase Agreement (SEPA), a type of equity line of credit (ELOC) that allows the company to direct Yorkville to purchase shares at a variable price tied to volume-weighted average price (VWAP), with a discount of 3–5%. Because the pricing resets to market on each drawdown, there is no fixed floor protecting existing shareholders from dilution at progressively lower prices. If the full facility is utilized, the company's share count would expand to approximately 1.08 billion ordinary shares.
Layered Convertible Overhang
The SEPA facility does not exist in isolation. Trinity Biotech also carries a $96.2 million convertible note held by Perceptive Advisors, of which $60 million is convertible at 97% of VWAP with a conversion floor of $1.03 per ADS. That instrument alone carries an estimated additional overhang of up to approximately 1.41 billion ordinary shares, depending on the price at which conversion occurs. Combined with the Yorkville facility, the two structures create a theoretical dilution pipeline that dwarfs the current outstanding count by a wide margin.
Current Price Below Convertible Floor
The company's ADS last traded at approximately $0.69, well below the $1.03 Perceptive conversion floor. When a stock trades below the floor price embedded in a convertible instrument, the conversion mechanism is effectively frozen at that tranche — but it also signals that the market is pricing in structural pressure from the variable-priced SEPA, which has no such floor.
Trinity Biotech is simultaneously contending with two active Nasdaq compliance notices: one for failing to maintain a minimum bid price of $1.00 per ADS, and another related to minimum market value of publicly held shares (MVPHS). These compliance clocks add a procedural layer of complexity to the capital structure, as the company may need to draw on the SEPA to fund operations while also needing its share price to recover to avoid delisting.
Balance Sheet Context
As of the most recent reported period, Trinity Biotech carried approximately $134.6 million in total debt against negative shareholders' equity of roughly negative $54.7 million. The SEPA facility functions as a financing mechanism for a company whose balance sheet leaves limited room for traditional debt issuance.
The variable-price, no-floor structure of the Yorkville SEPA means each drawdown is priced at a discount to prevailing market prices at the time of issuance, with the discount widening in effective terms during periods of lower trading volume or declining price. The filing's 3–5% VWAP discount is calculated over a short lookback window, a structure that concentrates pricing sensitivity into narrow trading periods.